Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types

被引：1
|
作者：
Mills, David
Kim, Ji Young
Wood, Erica
Tatsukawa, Keith
Knudsen, Nick
Nelson, Jay
Skidmore, Lillian
Kedar, G. C.
Tran, Hon
Pal, Manoj
Hashemi, Hamidreza
Buechler, Ying
Zhang, Shawn
O'Connor, Dan
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6352
引用
收藏
页数：2
相关论文
共 6 条
  • [1] Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate
    Kang, Mingchao
    Moon, Sung-Ju
    Kim, Ji Young
    Beck, Andy
    Allen, Molly
    Nelson, Jay
    Tatsukawa, Keith
    Tran, Hon
    Pal, Manoj
    Gray, Michael
    Knudsen, Nick
    Skidmore, Lillian
    Mills, David
    Lu, Yingchun
    Buechler, Ying
    Sakamuri, Sukumar
    Zhang, Shawn
    Tian, Feng
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Skidmore, Lillian K.
    Mills, David
    Kim, Ji Young
    Knudsen, Nick A.
    Nelson, Jay D.
    Pal, Manoj
    Wang, Jianing
    Kedar, G. C.
    Gray, Michael J.
    Barkho, Wisam
    Shastri, Prathap Nagaraja
    Ramprasad, Mysore P.
    Tian, Feng
    O'Connor, Daniel
    Buechler, Ying J.
    Zhang, Shawn Shao-Hui
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (12) : 1842 - 1853
  • [3] Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors
    Ma, Dangshe
    Narayanan, Bitha
    Marquette, Kim
    Graziani, Edmund
    Loganzo, Frank
    Charati, Manoj
    Prashad, Nadira
    Tumey, Nathan
    Golas, Jon
    Hosselet, Christine
    Hu, George
    Barletta, Frank
    Betts, Alison
    Lucas, Judy
    O'Donnell, Chris
    Tchistiakova, Lioudmila
    Gerber, Hans-Peter
    Sapra, Puja
    CANCER RESEARCH, 2016, 76
  • [4] Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers
    Humphreys, Robin C.
    Kirtely, Jessica
    Hewit, Amha
    Biroc, Sandra
    Knudsen, Nick
    Skidmore, Lillian
    Wahl, Alan
    CANCER RESEARCH, 2015, 75
  • [5] Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) for Breast Cancer Treatment
    Shastri, Prathap Nagaraja
    Zhu, Jingjing
    Skidmore, Lillian
    Liang, Xuejun
    Ji, Yanping
    Gu, Yi
    Tian, Feng
    Yao, Sulan
    Xia, Gang
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (09) : 1822 - 1832
  • [6] RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
    Strop, Pavel
    Tran, Thomas-Toan
    Dorywalska, Magdalena
    Delaria, Kathy
    Dushin, Russell
    Wong, Oi Kwan
    Ho, Wei-Hsien
    Zhou, Dahui
    Wu, Aidong
    Kraynov, Eugenia
    Aschenbrenner, Laura
    Han, Bora
    O'Donnell, Christopher J.
    Pons, Jaume
    Rajpal, Arvind
    Shelton, Dave L.
    Liu, Shu-Hui
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (11) : 2698 - 2708
1